Formulation and Evaluation of an Effervescent, Gastroretentive Drug-Delivery System - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Formulation and Evaluation of an Effervescent, Gastroretentive Drug-Delivery System
The authors developed a formulation for effervescent gastroretentive drug delivery techniques using ibuprofen as a model drug. They optimized the formulations by applying full factorial design.


Pharmaceutical Technology
Volume 10, Issue 34, pp. 60-71

References

1. L.F. Prescott and W.S. Nimmo, Novel Drug Delivery and Its Therapeutic Application, F.L. Prescott, Ed. (John Wiley and Sons, Oxford, UK, 1989), pp. 1–11.

2. Y.W. Chien, "Controlled and Modulated-Release Drug Delivery Systems," in Encyclopedia of Pharmaceutical Technology, J. Swarbrick and J.C. Boylan, Eds. (Marcel Dekker, New York, 1990), p. 280.

3. G. Chawla et al., Pharm. Technol. 27 (7), 50–68 (2003).

4. Medicines Complete, "Ibuprofen/Indomethacin," http://www.medicinescomplete.com/mc/martindale/current, accessed Dec. 19, 2006.

5. J.C. Valle-Jones, J. Smith, and D. Rowely-Jones, Br. J. Clin. Pract. 38 (7), 353–358 (1984).

6. T.H. Kantor, Ann. Intern. Med. 91 (6), 877–882 (1979).

7. A. Avgerinos and S. Malamataris, Int. J. Pharm. 63 (1), 77–80 (1990).

8. N. Sarkar et al., Curr. Ther. Res. Clin. Exp. 44 (6), 11–21 (1988).

9. M. Galeon et al., Curr. Ther. Res. Clin. Exp. 29 (4), 217–234 (1981).

10. S. Bolton and Charles Bon, "Factorial Designs," in Pharmaceutical Statistics: Practical and Clinical Applications, J. Swarbrick, Ed. (Marcel Dekker, New York, 3rd ed., 1984), pp. 265–285.

11. N.A. Armstrong and K.C. James, "Factorial Designs of Experiments," in Understanding Experimental Design and Interpretation in Pharmaceutics, (Ellis Harwood, London, 1990), pp. 27–54.

12. R. Ziyaur, A. Mushir, and R.K. Khar, Acta Pharm. 56 (2), 49–57 (2006).

13. N. Tomoya et al., Chem. Pharm. Bull. 54 (6), 14–51 (2006).

14. B.S. Dave, A.F. Amin, and M.M. Patel, AAPS PharmSciTech 5 (2), 45–49 (2004).

15. USP 27–NF 22 (USP, Rockville, MD, 2003), pp. 953–955.

16. M. Rosa, H. Zia, and T. Rhodes, Int. J. Pharm. 105 (34), 65–70 (1994).

17. G.S. Banker and N.R. Anderson, "Tablets," in The Theory and Practice of Industrial Pharmacy, L. Lachmann, H.A. Liberman, and J.L. Kaing, Eds. (Varghese Publishing House, Mumbai, 3rd ed., 1987), pp. 295–299.

18. "Tablets" (Indian Pharmacopoeia, (Controller of Publication, Delhi, India, Vol. II, 1996), pp. 734–736.

19. J. Castellanos, M.R.H. Zia, and C.T. Rhodes, Int. J. Pharm. 105 (34), (Apr25), 65–70 (1994).

20. J.E. Devereux, J.M. Newton, and M.B. Short, J. Pharm. Pharmacol. 42 (8), 500–501 (1990).

21. V.S. Chitnis, V.S. Malshe, and J.K. Lalla, Drug Dev. Ind. Pharm. 17 (10), 879–892 (1991).

22. G.M. Khan, Sciences 1 (8), 350–354 (2001).

23. D.M. Morkhade, Indian J. Pharm. Sci. 68 (3), 53–58 (2006).

24. T. Higuchi, J. Pharm. Sci. 52 (12), 1145–1149 (1963).

25. N.A. Peppas and J.J. Sahlin, Int. J. Pharm. 57 (1), 169–172 (1989).


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerRelationship-building at Top of Mind for Clients
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerRisk Reduction Top Driver for Biopharmaceutical Raw Material Development
Jill Wechsler Regulatory Watch Jill Wechsler Changes and Challenges for Generic Drugs
Faiz Kermaini Industry Insider Faiz KermainiNo Signs of a Slowdown in Mergers
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Source: Pharmaceutical Technology,
Click here